[
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1b study results for its CAR T-cell therapy, JNJ-90014496, indicating potential efficacy in treating large B-cell lymphoma. During the same period, the company saw a 7% share price increase. While the broader market remained flat over the last 7 days, Johnson & Johnson's advancements in cancer treatment likely added weight to its positive stock movement. Other positive developments, such as promising results in acute myeloid...",
    "url": "https://finnhub.io/api/news?id=f4de96322e56d6ec25f9b700eccc21fb455bf2e954e62f57fe69e9760414d1ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749921393,
      "headline": "Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma",
      "id": 135273774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1b study results for its CAR T-cell therapy, JNJ-90014496, indicating potential efficacy in treating large B-cell lymphoma. During the same period, the company saw a 7% share price increase. While the broader market remained flat over the last 7 days, Johnson & Johnson's advancements in cancer treatment likely added weight to its positive stock movement. Other positive developments, such as promising results in acute myeloid...",
      "url": "https://finnhub.io/api/news?id=f4de96322e56d6ec25f9b700eccc21fb455bf2e954e62f57fe69e9760414d1ee"
    }
  },
  {
    "ts": null,
    "headline": "UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite’s team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. The stock has gained over 9% in […]",
    "url": "https://finnhub.io/api/news?id=83bf14f8daf3391ac35972137fc25a05e5ee4b370992015514f1eb4572f7e2d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749864636,
      "headline": "UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times",
      "id": 135270160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite’s team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. The stock has gained over 9% in […]",
      "url": "https://finnhub.io/api/news?id=83bf14f8daf3391ac35972137fc25a05e5ee4b370992015514f1eb4572f7e2d7"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)",
    "summary": "When investors think of artificial intelligence (AI), names like Nvidia (NVDA), Palantir (PLTR), and Alphabet (GOOGL) typically come to mind. But AI’s impact extends well beyond the traditional tech sector. A standout example is Intuitive Surgical (ISRG), the clear global leader in robotic surgery, now making significant strides in integrating AI into healthcare. The company’s latest system, the da Vinci 5, incorporates AI capabilities that could unlock a powerful new and recurring revenue strea",
    "url": "https://finnhub.io/api/news?id=d805b9ee41b2ca7358f24b5fa64aa92c4ce85f1445aff6fcedce5b5a31ee23a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749862560,
      "headline": "Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)",
      "id": 135258011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "When investors think of artificial intelligence (AI), names like Nvidia (NVDA), Palantir (PLTR), and Alphabet (GOOGL) typically come to mind. But AI’s impact extends well beyond the traditional tech sector. A standout example is Intuitive Surgical (ISRG), the clear global leader in robotic surgery, now making significant strides in integrating AI into healthcare. The company’s latest system, the da Vinci 5, incorporates AI capabilities that could unlock a powerful new and recurring revenue strea",
      "url": "https://finnhub.io/api/news?id=d805b9ee41b2ca7358f24b5fa64aa92c4ce85f1445aff6fcedce5b5a31ee23a3"
    }
  }
]